A drug that activates glutamate receptors offers promise for a new class of anti-psychotic therapeutics and sheds light on the pathophysiology of this devastating disease (pages 1102–1107).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling
Psychopharmacology Open Access 10 March 2013
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Carlsson, A. & Lindquist, M. Acta Pharmacol. Toxicol. (Copenh.) 20, 140–144 (1963).
Creese, I., Burt, D.R. & Snyder, S.H. Science 192, 481–483 (1976).
Patil, S.T. et al. Nat. Med. 13, 1100–1105 (2007).
Anonymous. Nature 336, 95–96 (1998).
Ross, C.A., Margolis, R.L., Reading, S.A., Pletnikov, M., & Coyle, J.T. Neuron 52, 139–153 (2006).
Harrison, P.J. & Weinberger, D.R. Mol. Psychiatry 10, 40–68 (2005).
Tan, W. et al. J. Biol. Chem. 282, 24343–24351 (2007).
Egan, M.F. et al. Proc. Natl. Acad. Sci. USA 101, 12604–12609 (2004).
Aronica, E. et al. Eur. J. Neurosci. 17, 2106–2118 (2003).
Krystal, J.H. et al. Arch. Gen. Psychiatry 51, 199–214 (1994).
Lieberman, J.A. et al. N. Engl. J. Med. 353, 1209–1223 (2005).
Winterer, G. & Weinberger, D.R. Trends Neurosci. 27, 683–690 (2004).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Weinberger, D. Schizophrenia drug says goodbye to dopamine. Nat Med 13, 1018–1019 (2007). https://doi.org/10.1038/nm0907-1018
Issue Date:
DOI: https://doi.org/10.1038/nm0907-1018
This article is cited by
-
Specific activation of mGlu2 induced IGF-1R transactivation in vitro through FAK phosphorylation
Acta Pharmacologica Sinica (2019)
-
The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT1A signalling
Psychopharmacology (2013)
-
Group II Metabotropic Glutamate Receptor Agonist Ameliorates MK801-Induced Dysfunction of NMDA Receptors via the Akt/GSK-3β Pathway in Adult Rat Prefrontal Cortex
Neuropsychopharmacology (2011)
-
Neue Erkenntnisse zur Genetik der Schizophrenie
Der Nervenarzt (2009)
-
Cytoarchitecture cérébrale dans la schizophrénie
PSN (2009)